You are here: Industry Insights > NRDL

News List

The New NRDL Becomes Official: Many New Oncology Drugs Are Listed and Some Immune Drugs Become Affordable PharmaSources/Xiaobin
January 07, 2021
The National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2020) (“NRDL”) of China was released by the NHSA and Ministry of Human Resources and Social Security of China.
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy PharmaSources
January 09, 2025
Everest Medicines announced NEFECON(R) will apply NRDL pricing, benefiting IgAN patients.
A Review of the Policies/Events in 2019 PharmaSources/Suyi
January 15, 2020
5 policies in 2019 will affect China’s pharmaceutical market in 2020, which mainly involve China’s national medical insurance payment and pharmaceutical product cost control.
Speeding up review and guaranteeing payments: Blockbuster innovative drugs becoming truly accessible in China En-CPhI.CN
January 14, 2020
The negotiated national reimbursement drug list (NRDL) of China in 2019 was issued on Nov. 28, 2019 as scheduled!